Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 8975 results

  1. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    Awaiting development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    In development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Norucholic acid for treating primary sclerosing cholangitis [ID6583]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 April 2026.

    Technology appraisal guidance
    In consultation

  5. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

    Health technology evaluations
    In development

  6. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

    NICE guideline
    In development

  7. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  10. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  11. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  12. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  14. Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  15. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 7 April 2026.

    Technology appraisal guidance
    In consultation